Tagged with M

Zambon You declared in a recent interview that Zambon Group will always keep complying with the vision of your father Alberto, who has always refused acquisition offers from multinationals- a striking approach, in a context of pharmaceutical clusters when so many Italian players have been swallowed by wider structures. Which specific…

CROM You are specialised in Cardiology at Padua University, in Tropical Medicine and Hygiene at London University and in Pharmacology at Modena University, in Communication at Bocconi University in Milan, and also have 12 years of experience in all aspects of drug development in a major international pharmaceutical company. What aspect…

CANIFARMA This is your third interview with Focus Reports. In 2004 and 2008 you were Director of AMIIF, before that you were Director of ANAFAM, and now we’re delighted to be interviewing you as General Director of CANIFARMA with over 30 years of experience in the industry. There have been a…

Menarini After 67 years in the pharmaceutical industry, of which 45 at the head of Menarini, what would you say have been your personal keys to success? Most of my life, I worked three shifts. Meaning arriving at the office at 8:30am, come back home at 1pm, back to work at…

ADM Korea How did you first get involved in clinical trials and what inspired you to create your own CRO, ADM Korea? When I was working at CJ, the company was starting to produce bimolecular products, specifically they were working on vaccines. CJ needed personnel with expertise in this area and I…

Italfarmaco Italfarmaco counts amongst the few players who really sustained the growth of the Italian pharmaceutical industry in the past 10 years. Which specific values would you quote as keys to success that enabled the company not to fail like others and get where it is today, keeping growing organically yet…

CANIFARMA There have been quite a few regulatory changes in the last few years such as the new drug registration process and the suppression of the local plant rule. COFEPRIS has also grown in power since it was started 10 years ago. What has struck you as the most impactful change…

Korea Pharmaceutical Manufacturers Associatio Could you please introduce KPMA and explain the role it plays within the South Korean pharmaceutical industry? KPMA is the only association in South Korea regrouping the whole range of pharmaceutical companies, and therefore plays a pivotal role in advancing the industry in the country. We encourage and support our…

Finderm Finderm is the result of a courageous entrepreneurial experience, since you initiated the operations in 1995, in the most challenging times for the Italian pharmaceutical industry. Could you briefly introduce our readers the story behind Finderm and the main milestones and achievements since you started the operations? I personally started…

Daewoong Pharmaceutical What are the main milestones and achievements of Daewoong’s pharmaceutical business over its decades of evolution? Daewoong was first established in 1945 as Chosun Liver-oil Pharmaceutical Industry Co., Ltd. The company name was later changed to Daehan Vitamin in 1961, and again to the current name, Daewoong Pharmaceutical in 1978.…

Bristol-Myers Squibb The pharmaceutical industry in Asia is undergoing a period of specialization with R&D booming in places like Australia, Singapore and South Korea and manufacturing in places like China, India and now Vietnam – how does Indonesia fit into the overall picture? Indonesia has a number of very strong fundamental, macroeconomic…

Nordic Pharma France Nordic Pharma has been established in the French market since 2002 as one of its first steps towards internationalization. What have been the main milestones and achievements of Nordic in the French market since then? Since our establishment on the French market in 2002, Nordic Pharma has had a number…